Literature DB >> 23378230

Paraneoplastic brain stem encephalitis.

Franz Blaes1.   

Abstract

OPINION STATEMENT: Paraneoplastic brain stem encephalitis can occur as an isolated clinical syndrome or, more often, may be part of a more widespread encephalitis. Different antineuronal autoantibodies, such as anti-Hu, anti-Ri, and anti-Ma2 can be associated with the syndrome, and the most frequent tumors are lung and testicular cancer. Anti-Hu-associated brain stem encephalitis does not normally respond to immunotherapy; the syndrome may stabilize under tumor treatment. Brain stem encephalitis with anti-Ma2 often improves after immunotherapy and/or tumor therapy, whereas only a minority of anti-Ri positive patients respond to immunosuppressants or tumor treatment. The Opsoclonus-myoclonus syndrome (OMS) in children, almost exclusively associated with neuroblastoma, shows a good response to steroids, ACTH, and rituximab, some patients do respond to intravenous immunoglobulins or cyclophosphamide. In adults, OMS is mainly associated with small cell lung cancer or gynecological tumors and only a small part of the patients show improvement after immunotherapy. Earlier diagnosis and treatment seem to be one major problem to improve the prognosis of both, paraneoplastic brain stem encephalitis, and OMS.

Entities:  

Year:  2013        PMID: 23378230     DOI: 10.1007/s11940-013-0221-1

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  32 in total

1.  Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients.

Authors:  F Graus; F Keime-Guibert; R Reñe; B Benyahia; T Ribalta; C Ascaso; G Escaramis; J Y Delattre
Journal:  Brain       Date:  2001-06       Impact factor: 13.501

Review 2.  Rhombencephalitis / brainstem encephalitis.

Authors:  Burk Jubelt; Cornelia Mihai; Terrence M Li; Padma Veerapaneni
Journal:  Curr Neurol Neurosci Rep       Date:  2011-12       Impact factor: 5.081

3.  Treatment of neuroblastoma-related opsoclonus-myoclonus-ataxia syndrome with high-dose dexamethasone pulses.

Authors:  Florian Ertle; Wolfgang Behnisch; Naima Ali Al Mulla; Mohammed Bessisso; Dietz Rating; Gunhild Mechtersheimer; Barbara Hero; Andreas E Kulozik
Journal:  Pediatr Blood Cancer       Date:  2008-03       Impact factor: 3.167

4.  Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus.

Authors:  L Bataller; F Graus; A Saiz; J J Vilchez
Journal:  Brain       Date:  2001-02       Impact factor: 13.501

5.  Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study.

Authors:  Maarten J Titulaer; Lindsey McCracken; Iñigo Gabilondo; Thaís Armangué; Carol Glaser; Takahiro Iizuka; Lawrence S Honig; Susanne M Benseler; Izumi Kawachi; Eugenia Martinez-Hernandez; Esther Aguilar; Núria Gresa-Arribas; Nicole Ryan-Florance; Abiguei Torrents; Albert Saiz; Myrna R Rosenfeld; Rita Balice-Gordon; Francesc Graus; Josep Dalmau
Journal:  Lancet Neurol       Date:  2013-01-03       Impact factor: 44.182

6.  Anti-Ri: an antibody associated with paraneoplastic opsoclonus and breast cancer.

Authors:  F A Luque; H M Furneaux; R Ferziger; M K Rosenblum; S H Wray; S C Schold; M J Glantz; K A Jaeckle; H Biran; M Lesser
Journal:  Ann Neurol       Date:  1991-03       Impact factor: 10.422

7.  Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: clinical outcome and antineuronal antibodies-a report from the Children's Cancer Group Study.

Authors:  E Rudnick; Y Khakoo; N L Antunes; R C Seeger; G M Brodeur; H Shimada; R B Gerbing; D O Stram; K K Matthay
Journal:  Med Pediatr Oncol       Date:  2001-06

8.  Surface-binding autoantibodies to cerebellar neurons in opsoclonus syndrome.

Authors:  Franz Blaes; Verena Fühlhuber; Martina Korfei; Marlene Tschernatsch; Wolfgang Behnisch; Kevin Rostasy; Barbara Hero; Manfred Kaps; Klaus T Preissner
Journal:  Ann Neurol       Date:  2005-08       Impact factor: 10.422

9.  Chronic relapsing opsoclonus-myoclonus syndrome: combination of cyclophosphamide and dexamethasone pulses.

Authors:  B Wilken; M Baumann; C G Bien; B Hero; K Rostasy; F Hanefeld
Journal:  Eur J Paediatr Neurol       Date:  2007-07-10       Impact factor: 3.140

10.  Clinical analysis of anti-Ma2-associated encephalitis.

Authors:  Josep Dalmau; Francesc Graus; Alberto Villarejo; Jerome B Posner; Deborah Blumenthal; Brian Thiessen; Albert Saiz; Patricio Meneses; Myrna R Rosenfeld
Journal:  Brain       Date:  2004-06-23       Impact factor: 13.501

View more
  2 in total

Review 1.  CLIPPERS: chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids. Review of an increasingly recognized entity within the spectrum of inflammatory central nervous system disorders.

Authors:  A Dudesek; F Rimmele; S Tesar; S Kolbaske; P S Rommer; R Benecke; U K Zettl
Journal:  Clin Exp Immunol       Date:  2014-03       Impact factor: 4.330

Review 2.  Paraneoplastic Diseases of the Central Nervous System.

Authors:  Jonathan Galli; John Greenlee
Journal:  F1000Res       Date:  2020-03-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.